The Value of HPV Genotypes Combined with Clinical Indicators in the Classification of Cervical Squamous Cell Carcinoma and Adenocarcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Jul 15

PMID 35840910

Authors

Zhimin He

Rongsheng Chen

Shangying Hu

Yajiao Zhang

Yang Liu

Chengwei Li

Fajin Lv

Zhibo Xiao

Affiliations

Soon will be listed here.

Abstract

Background: To investigate the differences in HPV genotypes and clinical indicators between cervical squamous cell carcinoma and adenocarcinoma and to identify independent predictors for differentiating cervical squamous cell carcinoma and adenocarcinoma.

Methods: A total of 319 patients with cervical cancer, including 238 patients with squamous cell carcinoma and 81 patients with adenocarcinoma, were retrospectively analysed. The clinical characteristics and laboratory indicators, including HPV genotypes, SCCAg, CA125, CA19-9, CYFRA 21-1 and parity, were analysed by univariate and multivariate analyses, and a classification model for cervical squamous cell carcinoma and adenocarcinoma was established. The model was validated in 96 patients with cervical cancer.

Results: There were significant differences in SCCAg, CA125, CA19-9, CYFRA 21-1, HPV genotypes and clinical symptoms between cervical squamous cell carcinoma and adenocarcinoma (P < 0.05). Logistic regression analysis showed that SCCAg and HPV genotypes (high risk) were independent predictors for differentiating cervical squamous cell carcinoma from adenocarcinoma. The AUC value of the established classification model was 0.854 (95% CI: 0.804-0.904). The accuracy, sensitivity and specificity of the model were 0.846, 0.691 and 0.899, respectively. The classification accuracy was 0.823 when the model was verified.

Conclusion: The histological type of cervical cancer patients with persistent infection of high-risk HPV subtypes and low serum SCCAg levels was more prone to being adenocarcinoma. When the above independent predictors occur, the occurrence and development of cervical adenocarcinoma should be anticipated, and early active intervention treatment should be used to improve the prognosis and survival of patients.

Citing Articles

Identification of differentially expressed MiRNA clusters in cervical cancer.

Sriharikrishnaa S, Jishnu P, Varghese V, Shukla V, Mallya S, Chakrabarty S Discov Oncol. 2025; 16(1):172.

PMID: 39946028 PMC: 11825440. DOI: 10.1007/s12672-025-01946-0.

Gene Expression Analysis for Uterine Cervix and Corpus Cancer Characterization.

Almorox L, Antequera L, Rojas I, Herrera L, Ortuno F Genes (Basel). 2024; 15(3).

PMID: 38540371 PMC: 10970626. DOI: 10.3390/genes15030312.

HPV genotyping of cervical histologic specimens of 61, 422 patients from the largest women hospital in China.

Zhong F, Li Z, Sun Y, Xiao Y, Li J, Zhou X Front Oncol. 2023; 13:1161631.

PMID: 37064129 PMC: 10090690. DOI: 10.3389/fonc.2023.1161631.

References

Okonogi N, Wakatsuki M, Kato S, Karasawa K, Kiyohara H, Shiba S . Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). Cancer Med. 2018; 7(2):351-359. PMC: 5806111. DOI: 10.1002/cam4.1305. View

Balcacer P, Shergill A, Litkouhi B . MRI of cervical cancer with a surgical perspective: staging, prognostic implications and pitfalls. Abdom Radiol (NY). 2019; 44(7):2557-2571. DOI: 10.1007/s00261-019-01984-7. View

Wang C, Lai C, Huang H, Chao A, Chang C, Chang T . Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78(4):1111-20. DOI: 10.1016/j.ijrobp.2009.09.021. View

Molijn A, Jenkins D, Chen W, Zhang X, Pirog E, Enqi W . The complex relationship between human papillomavirus and cervical adenocarcinoma. Int J Cancer. 2015; 138(2):409-16. DOI: 10.1002/ijc.29722. View

Cuschieri K, Brewster D, Graham C, Nicoll S, Williams A, Murray G . Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer. Int J Cancer. 2014; 135(11):2721-6. DOI: 10.1002/ijc.28902. View

Kato H, Torigoe T . Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977; 40(4):1621-8. DOI: 10.1002/1097-0142(197710)40:4<1621::aid-cncr2820400435>3.0.co;2-i. View

Zhou J, Wu S, Sun J, Li F, Lin H, Chen Q . Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. J Cancer Res Clin Oncol. 2016; 143(1):115-122. DOI: 10.1007/s00432-016-2246-9. View

Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K . Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol. 2016; 28(2):e19. PMC: 5323286. DOI: 10.3802/jgo.2017.28.e19. View

Chen W, Molijn A, Enqi W, Zhang X, Jenkins D, Yu X . The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. Int J Cancer. 2016; 139(12):2687-2697. DOI: 10.1002/ijc.30401. View

10.

Berrington de Gonzalez A, Sweetland S, Green J . Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br J Cancer. 2004; 90(9):1787-91. PMC: 2409738. DOI: 10.1038/sj.bjc.6601764. View

11.

Lee S, Hong J, Yu M, Jeong S, Kim S, Kim Y . Serum conversion pattern of SCC-Ag levels between pre- and post-chemoradiotherapy predicts recurrence and metastasis in cervical cancer: a multi-institutional analysis. Clin Exp Metastasis. 2021; 38(5):467-474. DOI: 10.1007/s10585-021-10115-w. View

12.

Small Jr W, Bacon M, Bajaj A, Chuang L, Fisher B, Harkenrider M . Cervical cancer: A global health crisis. Cancer. 2017; 123(13):2404-2412. DOI: 10.1002/cncr.30667. View

13.

Okonogi N, Ando K, Murata K, Wakatsuki M, Noda S, Irie D . Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix. Cancers (Basel). 2021; 13(11). PMC: 8198465. DOI: 10.3390/cancers13112713. View

14.

Guo H, Bi X, Lei T, Lv X, Yao G, Chen Y . Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors. BMC Cancer. 2020; 20(1):441. PMC: 7236452. DOI: 10.1186/s12885-020-06928-9. View

15.

Chen P, Jiao L, Ren F, Wang D . Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma. BMC Cancer. 2020; 20(1):423. PMC: 7227060. DOI: 10.1186/s12885-020-06934-x. View

16.

Chen L, Luo T, Yang J, Wang K, Liu S, Wei Y . Assessment of serum synuclein-γ and squamous cell carcinoma antigen as diagnostic biomarkers in patients with oral squamous cell carcinoma and oral potentially malignant disorders. J Oral Pathol Med. 2020; 50(2):165-174. DOI: 10.1111/jop.13115. View

17.

Lehtovirta P, Viinikka L, Ylikorkala O . Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol Oncol. 1990; 37(2):276-8. DOI: 10.1016/0090-8258(90)90347-n. View

18.

Pan X, Yang W, Wen Z, Li F, Tong L, Tang W . Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis. J Gynecol Oncol. 2020; 31(6):e80. PMC: 7593229. DOI: 10.3802/jgo.2020.31.e80. View

19.

Jenkins D, Molijn A, Kazem S, Pirog E, Alemany L, de Sanjose S . Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. Int J Cancer. 2020; 147(9):2526-2536. DOI: 10.1002/ijc.33124. View

20.

Okamura A, Matsuda S, Mayanagi S, Kanamori J, Imamura Y, Irino T . Clinical Significance of Pretherapeutic Serum Squamous Cell Carcinoma Antigen Level in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2020; 28(2):1209-1216. DOI: 10.1245/s10434-020-08716-y. View